<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371745">
  <stage>Registered</stage>
  <submitdate>1/11/2016</submitdate>
  <approvaldate>7/11/2016</approvaldate>
  <actrnumber>ACTRN12616001527459</actrnumber>
  <trial_identification>
    <studytitle>A comparison of the plasma levels and safety of coenzyme Q10 from 4 different formulations in healthy adult volunteers.</studytitle>
    <scientifictitle>A comparison of the plasma levels and safety of coenzyme Q10 from 4 different formulations in healthy adult volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>CoQ10 deficiency </healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The aim of this study is to evaluate the absorption characteristics of FOUR Coenzyme Q10 PRODUCTS. ONE Coenzyme Q10 preparation will be self administered (orally) on Day 1 of each week. All participants will be allocated the same preparation each day, rotating products each week for 4 weeks. Participants will receive the four products in the order listed below. Allocation: non-randomised, Treatment Endpoint: Characteristics of Coenzyme Q10 in Blood levels, Intervention Model: oro-buccal or oral administration, Masking: non-blinded, Primary Purpose: absorption characteristics in blood plasma. Clinical Trial Coordinator to supervise dose administration and any adverse effects. Coenzyme Q10 preparations include:
1) Blackmores CoQ10= 150mg
2) Bioceuticals CoQ10 Liposome= 40mg
3) Bioceuticals Ubiquinol BioActive = 150mg
4) Medlab Clinicals NanoCelle CoQ10= 30mg</interventions>
    <comparator>Coenzyme Q10 preparations include:
1) Blackmores CoQ10= 150mg
2) Bioceuticals CoQ10 Liposome= 40mg
3) Bioceuticals Ubiquinol BioActive = 150mg
4) Medlab Clinicals NanoCelle CoQ10= 30mg</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>CoQ10 plasma serum measurement </outcome>
      <timepoint>Blood draws at baseline (0), 30, 60, 120, 180, 240 and 360 minutes via cannulation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety - Documentation of any adverse events. Side effects may include: stomach upset, loss of appetite, nausea, vomiting, and diarrhoea. CTC to report participants post administration by direct observation</outcome>
      <timepoint>Clinical Trial Coordinator to document any adverse events: subject to participant. Continuous monitoring after dose administered to 24 hours post administration.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Participants &gt; 18 years of age at time of entry on study 
2) Cognitive ability to understand informed consent process and to give informed consent to the experimental treatment 
3) Participants agree to undergo venipuncture on multiple occasions or have a catheter inserted
4) Participants agree to adhere to the study protocol 
5) No history of any chronic diseases 
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1) Any clinically relevant abnormal findings which, in the opinion of the investigators / clinicians, may put the participant at risk of adverse events because of participation in the clinical trial including: physical examination, clinical chemistry, haematology, urinalysis, vital signs
2) Any chronic diseases 
3) Alcohol abuse 
4) Pregnant or nursing an infant
5) Have not been prescribed (medications) or have administered Coenzyme Q10 or any other supplement or vitamin or mineral or herbal medicine in the last week  (note: participation will include a 1 week washout period)
6) Any psychiatric disorders by history or examination that would prevent completion of the study or result in possible adverse events for the participant
7) The use of illicit drugs 
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/12/2016</anticipatedstartdate>
    <actualstartdate>11/09/2017</actualstartdate>
    <anticipatedenddate>31/10/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <currentsamplesize>8</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medlab Clinical</primarysponsorname>
    <primarysponsoraddress>66 McCauley Street, Alexandria, NSW, 2015</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medlab Clinical </fundingname>
      <fundingaddress>66 McCauley Street, Alexandria, NSW, 2015</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to evaluate the absorption characteristics of FOUR COENZYME Q10 PRODUCTS. As such this study proposes to evaluate the absorption characteristics of these products by measuring the plasma concentrations following an oral dose. There is significant interest from researchers, general practitioners and the public re: the administration of Coenzyme Q10 supplements for health maintenance or disease treatments such as those with mild to moderate cardiovascular disease, and what differences exist in the absorption characteristics of different formulations.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Institute Of Integrative Medicine </ethicname>
      <ethicaddress>11-23 Burwood Rd, Hawthorn, VIC, 3122</ethicaddress>
      <ethicapprovaldate>9/09/2016</ethicapprovaldate>
      <hrec>0036E_2016</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Clinical. 66 McCauley Street, Alexandria, NSW, 2015</address>
      <phone>+61 02 8188 0311</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Serena Dal Forno</name>
      <address>Medlab Clinical. 66 McCauley Street, Alexandria, NSW, 2015</address>
      <phone>+61 02 8188 0311 Ext. 120</phone>
      <fax />
      <email>serena_dalforno@medlab.co</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Clinical. 66 McCauley Street, Alexandria, NSW, 2015</address>
      <phone>+61 02 8188 0311</phone>
      <fax />
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>